This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2003 Sep;14(9):2395-401.

doi: 10.1097/01.asn.0000086472.65806.73.

Aldosterone in chronic kidney and cardiac disease

Thomas H Hostetter¹, Hassan N Ibrahim

Affiliations

Affiliation

¹ National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892, USA. hostettert@wstra.niddk.nih.gov

PMID: 12937319
DOI: 10.1097/01.asn.0000086472.65806.73

Review

Aldosterone in chronic kidney and cardiac disease

Thomas H Hostetter et al. J Am Soc Nephrol. 2003 Sep.

. 2003 Sep;14(9):2395-401.

doi: 10.1097/01.asn.0000086472.65806.73.

Authors

Thomas H Hostetter¹, Hassan N Ibrahim

Affiliation

¹ National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892, USA. hostettert@wstra.niddk.nih.gov

PMID: 12937319
DOI: 10.1097/01.asn.0000086472.65806.73

No abstract available

PubMed Disclaimer

Similar articles

Aldosterone in heart and kidney diseases.
Rentoukas EI, Lazaros GA, Zirogiannis PN. Rentoukas EI, et al. Hellenic J Cardiol. 2005 Nov-Dec;46(6):408-19. Hellenic J Cardiol. 2005. PMID: 16422128 Review. No abstract available.
Renal and cardiac complications of hypertension.
Blumenfeld JD. Blumenfeld JD. Clin Symp. 1994;46(4):3-32. Clin Symp. 1994. PMID: 7874866 Review. No abstract available.
Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.
Bauersachs J, Jaisser F, Toto R. Bauersachs J, et al. Hypertension. 2015 Feb;65(2):257-63. doi: 10.1161/HYPERTENSIONAHA.114.04488. Epub 2014 Nov 3. Hypertension. 2015. PMID: 25368026 Review. No abstract available.
The renin-angiotensin-aldosterone system in parenchymal kidney disease.
Maxwell MH, Weidmann P. Maxwell MH, et al. Adv Nephrol Necker Hosp. 1975;5:301-32. Adv Nephrol Necker Hosp. 1975. PMID: 171933 Review. No abstract available.
[Chronic kidney disease and the aldosterone/mineralocorticoid receptor system].
Nagase M, Fujita T. Nagase M, et al. Nihon Jinzo Gakkai Shi. 2010;52(2):125-31. Nihon Jinzo Gakkai Shi. 2010. PMID: 20415233 Review. Japanese. No abstract available.

See all similar articles

Cited by

Potential of Modulating Aldosterone Signaling and Mineralocorticoid Receptor with microRNAs to Attenuate Diabetic Kidney Disease.
Hagiwara S, Gohda T, Kantharidis P, Okabe J, Murakoshi M, Suzuki Y. Hagiwara S, et al. Int J Mol Sci. 2024 Jan 10;25(2):869. doi: 10.3390/ijms25020869. Int J Mol Sci. 2024. PMID: 38255942 Free PMC article. Review.
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.
Appel LJ, Wright JT Jr, Greene T, Kusek JW, Lewis JB, Wang X, Lipkowitz MS, Norris KC, Bakris GL, Rahman M, Contreras G, Rostand SG, Kopple JD, Gabbai FB, Schulman GI, Gassman JJ, Charleston J, Agodoa LY; African American Study of Kidney Disease and Hypertension Collaborative Research Group. Appel LJ, et al. Arch Intern Med. 2008 Apr 28;168(8):832-9. doi: 10.1001/archinte.168.8.832. Arch Intern Med. 2008. PMID: 18443258 Free PMC article. Clinical Trial.
Aldosterone and mortality in hemodialysis patients: role of volume overload.
Hung SC, Lin YP, Huang HL, Pu HF, Tarng DC. Hung SC, et al. PLoS One. 2013;8(2):e57511. doi: 10.1371/journal.pone.0057511. Epub 2013 Feb 28. PLoS One. 2013. PMID: 23469009 Free PMC article.
Exosome‑encapsulated miR‑26a attenuates aldosterone‑induced tubulointerstitial fibrosis by inhibiting the CTGF/SMAD3 signaling pathway.
Zheng H, Ji J, Zhao T, Wang E, Zhang A. Zheng H, et al. Int J Mol Med. 2023 Feb;51(2):11. doi: 10.3892/ijmm.2022.5214. Epub 2022 Dec 16. Int J Mol Med. 2023. PMID: 36524378 Free PMC article.
Loss of Histone H3 K79 Methyltransferase Dot1l Facilitates Kidney Fibrosis by Upregulating Endothelin 1 through Histone Deacetylase 2.
Zhang L, Chen L, Gao C, Chen E, Lightle AR, Foulke L, Zhao B, Higgins PJ, Zhang W. Zhang L, et al. J Am Soc Nephrol. 2020 Feb;31(2):337-349. doi: 10.1681/ASN.2019070739. Epub 2019 Dec 16. J Am Soc Nephrol. 2020. PMID: 31843983 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Wolters Kluwer
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information